Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 17/20 | 0.55 |
| ▸ | PRKG1 | Q13976 | 4/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.49 |
| ▸ | PRKCG | P05129 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | AKT2 | P31751 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.49 |
| ▸ | NEK4 | P51957 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
| ▸ | PRKG2 | Q13237 | 2/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18254791 | 1.00 | ROCK2 (0.55) | ROCK2ROCK1PRKG1CHEK1RPS6KA5 | |
| SCHEMBL18254876 | 0.88 | ROCK1 (0.69) | ROCK2ROCK1PRKG1CHEK1RPS6KA5 | |
| SCHEMBL20181399 | 0.79 | ROCK2 (0.69) | ROCK2ROCK1PRKACAGSK3AGSK3B | |
| SCHEMBL18254895 | 0.77 | ROCK2 (0.60) | ROCK2ROCK1PRKG1PRKACAMAPK1 | |
| SCHEMBL13376861 | 0.77 | ROCK1 (0.65) | ROCK2ROCK1PRKACACDK2CYP3A4 | |
| SCHEMBL21908699 | 0.77 | ROCK2 (0.43) | ROCK2ROCK1PRKG1CHEK1RPS6KA5 | |
| SCHEMBL18254917 | 0.75 | ROCK1 (0.60) | ROCK2ROCK1PRKG1CHEK1RPS6KA5 | |
| SCHEMBL14348311 | 0.74 | ROCK1 (0.53) | ROCK2ROCK1PRKG1CHEK1RPS6KA5 | |
| SCHEMBL20181594 | 0.74 | ROCK2 (0.79) | ROCK2ROCK1PRKG1RPS6KA5PRKCG | |
| SCHEMBL20181640 | 0.74 | ROCK2 (0.79) | ROCK2ROCK1PRKG1RPS6KA5PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200255448-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2020-08-13 | — | — | US | disclosed |
| US-10633393-B2 | Heterocyclic compounds as kinase inhibitors | Translational Drug Development (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-09-19 | — | — | US | disclosed |
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885PRKG1 120/4885 |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885PRKG1 120/4885 |
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885PRKG1 120/4885 |
| US-10633393-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885PRKG1 120/4885 |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885PRKG1 120/4885 |
| US-20200255448-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885PRKG1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.